Understand the source comparison
LIPO-C Legal 2026 Status: [Research vs Clinical Use] Comparison
Legal Basis 21 CFR 312.2(b)(1) investigational use exemption Section 503A/503B patient-specific compounding None. Requires FDA drug approval Research peptides are federally protected; clinical requires prescription; bulk products face enforcement Prescription
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Legal Basis
- 21 CFR 312.2(b)(1) investigational use exemption
- Section 503A/503B patient-specific compounding
- None. Requires FDA drug approval
- Research peptides are federally protected; clinical requires prescription; bulk products face enforcement
- Prescription Required
- No. Sold to institutions
- Yes. Individualised Rx per patient
- Claimed 'no' but legally required
- Only clinical pathway allows individual consumer access, and only with valid Rx
- Buyer Verification
- Institutional affiliation required
- Prescriber-patient relationship verified
- Often none or minimal
- Legitimate suppliers verify research credentials or prescriber licensure
- Permitted Marketing Claims
- None. 'for research use only'
- None. Compounded under prescription
- Often make therapeutic claims illegally
- Therapeutic claims without approval = federal violation
- Supplier Registration
- FDA-registered peptide manufacturer
- State-licensed pharmacy (503A) or FDA-registered outsourcing facility (503B)
- Often unregistered or foreign
- Registration status determines enforcement risk
- Primary Enforcement Risk
- Minimal if compliance maintained
- State pharmacy board oversight
- High. FDA Warning Letters common
- Research and compliant clinical pathways are low-risk; grey-market bulk sales face active enforcement
- The key differentiator: intended use. A peptide sold with a certificate of analysis to a university biochemistry lab is research. The same peptide sold to an individual consumer with dosing instructions on the website is an unapproved drug.